azomycin has been researched along with cci 103f in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 12 (50.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cline, JM; LaDine, JK; Raleigh, JA; Rathman, M; Thrall, DE; Zeman, EM | 1 |
| Cline, JM; Franko, AJ; Page, RL; Raleigh, JA; Thrall, DE | 1 |
| Beckman, W; Gill, M; Joseph, AP; Kwock, L; McMurry, HL; Raleigh, JA | 1 |
| Allen, PS; Franko, AJ; Kelly, DA; Raleigh, JA; Trimble, LA | 1 |
| Jin, GY; Li, SJ; Moulder, JE; Raleigh, JA | 1 |
| Jin, GY; Li, SJ; Moulder, JE | 1 |
| Best, MW; Franko, AJ; Koch, CJ; Miller, GG; Raleigh, JA | 1 |
| Griffiths, JR; Maxwell, RJ; Workman, P | 1 |
| Franko, AJ; Fuciarelli, AF; Kelly, DA; Koch, CJ; Miller, GG; Raleigh, JA | 1 |
| Allen, PS; Franko, AJ; Lunt, JA; Raleigh, JA; Treiber, EO | 1 |
| Calkins, DP; McEntee, MC; Raleigh, JA; Thrall, DE; Zeman, EM | 1 |
| Cline, JM; McEntee, MC; Raleigh, JA; Thrall, DE | 1 |
| Cline, JM; Raleigh, JA; Rosner, GL; Thrall, DE | 2 |
| Cline, JM; La Dine, JK; Raleigh, JA; Thrall, DE | 1 |
| Azuma, C; McEntee, MC; Raleigh, JA; Rosner, GL; Thrall, DE | 1 |
| Bussink, J; Denekamp, J; Ljungkvist, AS; Raleigh, JA; Rijken, PF; Van Der Kogel, AJ | 1 |
| Bennewith, KL; Durand, RE; Raleigh, JA | 1 |
| Bussink, J; Heerschap, A; Lok, J; Punt, CJ; van Der Kogel, AJ; van Laarhoven, HW | 1 |
| Bennewith, KL; Durand, RE | 1 |
| Begg, AC; Bussink, J; Kaanders, JH; Ljungkvist, AS; Raleigh, JA; Rijken, PF; van der Kogel, AJ | 1 |
| Chou, SC; Ji, X; Kleiter, MM; Lee, DY; Malarkey, DE; Raleigh, JA; Thrall, DE | 1 |
| An, H; Engenhart-Cabillic, R; Eul, BG; Fokas, E; Hänze, J; Heverhagen, JT; Kamlah, F; Keil, B; Lang, N; Rose, F | 1 |
| Ashcroft, M; Baker, LC; Boult, JK; Burrell, JS; Gilmour, LD; Griffiths, JR; Howe, FA; Jamin, Y; Raleigh, JA; Robinson, SP; van der Kogel, AJ; Walker-Samuel, S | 1 |
24 other study(ies) available for azomycin and cci 103f
| Article | Year |
|---|---|
Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.
Topics: Animals; Cell Hypoxia; Dogs; Enzyme-Linked Immunosorbent Assay; Liposarcoma; Neoplasms; Nitroimidazoles; Sarcoma, Synovial | 1992 |
Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.
Topics: Animals; Cell Hypoxia; Dog Diseases; Dogs; Immunohistochemistry; Neoplasms; Nitroimidazoles; Staining and Labeling | 1990 |
Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry.
Topics: Adenocarcinoma; Animals; Cell Hypoxia; Evaluation Studies as Topic; Immunohistochemistry; Magnetic Resonance Spectroscopy; Male; Nitroimidazoles; Prostatic Neoplasms; Rats | 1992 |
Development of an in vivo 19F magnetic resonance method for measuring oxygen deficiency in tumors.
Topics: Adenocarcinoma; Animals; Carcinoma 256, Walker; Cell Hypoxia; Female; Magnetic Resonance Spectroscopy; Male; Nitroimidazoles; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Tritium | 1991 |
Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy.
Topics: Animals; Cell Hypoxia; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles | 1990 |
Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by [1H]/[19F] magnetic resonance spectroscopy.
Topics: Animals; Cell Hypoxia; Cell Survival; Gamma Rays; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Nitroimidazoles; Radiation Tolerance; Radiography; Radionuclide Imaging; Tumor Cells, Cultured | 1991 |
Quantitation of hypoxia in multicellular spheroids by video image analysis.
Topics: Autoradiography; Cell Aggregation; Cell Line; Fluorescence; Humans; Image Processing, Computer-Assisted; Immunoenzyme Techniques; Neoplasms; Nitroimidazoles; Oxygen | 1989 |
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
Topics: Animals; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1989 |
Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours.
Topics: Animals; Carcinoma 256, Walker; Female; Immunohistochemistry; Male; Microscopy, Fluorescence; Misonidazole; Nitroimidazoles; Oxygen; Rabbits; Tumor Cells, Cultured | 1987 |
Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T.
Topics: Animals; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Oxygen | 1986 |
Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors.
Topics: Animals; Biomarkers, Tumor; Biopsy; Carcinoma, Basal Cell; Cell Division; Cell Hypoxia; Dog Diseases; Dogs; Immunohistochemistry; Nitroimidazoles; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured | 1995 |
ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation.
Topics: Animals; Cell Hypoxia; Dogs; Enzyme-Linked Immunosorbent Assay; Neoplasms, Experimental; Nitroimidazoles | 1994 |
Distribution of the hypoxia marker CCI-103F in canine tumors.
Topics: Animals; Cell Hypoxia; Dog Diseases; Dogs; Female; Male; Neoplasms; Nitroimidazoles | 1994 |
An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.
Topics: Animals; Biomarkers, Tumor; Calibration; Dogs; Enzyme-Linked Immunosorbent Assay; Hypoxia; Neoplasms; Nitroimidazoles; Tissue Distribution; Tritium | 1994 |
Quantification of CCI-103F labeling heterogeneity in canine solid tumors.
Topics: Analysis of Variance; Animals; Biomarkers; Cell Hypoxia; Dog Diseases; Dogs; Neoplasms; Nitroimidazoles; Oxygen; Reproducibility of Results | 1997 |
Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning.
Topics: Animals; Biopsy; Cell Hypoxia; Dog Diseases; Dogs; Neoplasms; Nitroimidazoles | 1997 |
Changes in tumor hypoxia measured with a double hypoxic marker technique.
Topics: Animals; Benzimidazoles; Biomarkers; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Hypoxia; Endothelium, Vascular; Fluorescent Dyes; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2000 |
Orally administered pimonidazole to label hypoxic tumor cells.
Topics: Administration, Oral; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Flow Cytometry; Humans; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nitroimidazoles; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters.
Topics: Animals; Benzimidazoles; Bromodeoxyuridine; Carbon Dioxide; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Female; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Niacinamide; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 2004 |
Quantifying transient hypoxia in human tumor xenografts by flow cytometry.
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Female; Flow Cytometry; Humans; Mice; Mice, SCID; Nitroimidazoles; Oxygen; Partial Pressure; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2004 |
Hypoxic cell turnover in different solid tumor lines.
Topics: Animals; Benzimidazoles; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Coloring Agents; Half-Life; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nitroimidazoles; Time Factors | 2005 |
A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker.
Topics: Administration, Oral; Animals; Area Under Curve; Cell Hypoxia; Cell Line; Cricetinae; Cricetulus; Dog Diseases; Dogs; Feasibility Studies; Hydrogen-Ion Concentration; Injections, Intravenous; Neoplasms; Nitroimidazoles | 2006 |
Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzimidazoles; Biomarkers; Caspase 3; Cell Hypoxia; Contrast Media; Gadolinium; Glucose Transporter Type 1; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Nitroimidazoles; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Transplantation, Heterologous | 2010 |
Evaluation and immunohistochemical qualification of carbogen-induced ΔR₂ as a noninvasive imaging biomarker of improved tumor oxygenation.
Topics: Animals; Biomarkers; Carbon Dioxide; Cell Hypoxia; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Nitroimidazoles; Oxygen; Oxygen Consumption; Partial Pressure; Pituitary Neoplasms; Prolactinoma | 2013 |